FDA: COVID-19 vaccine choice in pregnancy is personal
Federal health officials have pulled back a key recommendation that pregnant women get the COVID-19 vaccine -- causing sharp criticism from doctors and other experts.
The announcement came Tuesday from Health and Human Services Secretary Robert F. Kennedy Jr., who said the government will no longer recommend COVID shots for healthy children or pregnant women.
Dr. Marty Makary, head of the U.S. Food and Drug Administration (FDA), said Wednesday that the decision should be made between a pregnant woman and her doctor.
"The data on the COVID vaccine booster in pregnant women is a mixed set of data," Makary said in an interview. "Now, I think the decision should be between a doctor and a pregnant woman."
The U.S. Centers for Disease Control and Prevention (CDC) usually relies on a panel of vaccine experts to review studies and make public health recommendations. This process was skipped in making the COVID recommendation.
The CDC, which currently has no director, still hasn't updated its website to reflect the change.
Its advice plays a major role in insurance coverage. If the CDC no longer recommends a vaccine, many patients may be unable to get it for free.
The CDC has said pregnant women are more likely to become seriously sick from COVID than people who aren't pregnant.
Dr. Beverly Gray, an OB-GYN at Duke Health in Durham, N.C., told NBC News she'll keep recommending the shot to her patients.
"The evidence is [overwhelmingly] clear that it reduces the risk of miscarriage, risk of ICU admissions, risk of death," Gray said. "And as an obstetrician-gynecologist who cared for patients through the COVID pandemic and who cared for patients who lost their pregnancies, there are really scary consequences of getting an infection."
She said this sudden change may cause more confusion for pregnant people trying to make informed decisions.
"It's really heartbreaking to see this movement against science and data," Gray said.
Dr. Jesse Goodman, a former FDA chief scientist, said he hasn't seen any "mixed" data about the COVID shot in pregnancy.
"I am aware of multiple studies that have shown the benefit of COVID vaccines in protecting pregnant women, who are very clearly at very high risk of more severe outcomes from COVID," he told NBC News. "Several studies have also shown that maternal immunization helps protect against illness and hospitalizations in infants less than 6 months old."
Dr. Paul Offit, head of the Vaccine Education Center at Children's Hospital of Philadelphia, agreed.
He said pregnant women are 1.5 to 2 times more likely to be hospitalized or die from COVID.
"It seems to be that the burden of proof on not recommending for pregnancy is on [the government] to prove that it really isn't a value anymore," Offit said.
Tuesday's announcement was made without anyone from the CDC present.
Makary said "many scientists" were involved in the discussions but didn't confirm if any were from the CDC.
He also wouldn't say whether the government would release any data supporting the recommendation.
The American College of Obstetricians and Gynecologists (ACOG) called the move "extremely disappointing," NBC News reported.
"We also understand that despite the change in recommendations from HHS, the science has not changed," the group said in a statement. "It is very clear that COVID infection during pregnancy can be catastrophic and lead to major disability."
More information
The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccination.
Copyright © 2025 HealthDay. All rights reserved.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
26 minutes ago
- Newsweek
Marjorie Taylor Greene Fumes Over Vaccine Approval: 'Not MAHA at All'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Marjorie Taylor Greene has spoken out against a new COVID-19 vaccine being approved in the United States, saying the move is "not MAHA at all." Why It Matters Health Secretary Robert F. Kennedy Jr. is facing repeated backlash for some of his positions on health and medicine, including from people who would ordinarily support him. In May, prominent members of the Make America Great Again movement, including Nicole Shanahan, Kennedy's former presidential running mate, and media personality Laura Loomer, spoke out against Kennedy Jr.'s pick for U.S. Surgeon General Casey Means. In March, Kennedy Jr. sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. Marjorie Taylor Greene, R-Ga., arrives for a meeting of House Republicans in the Capitol Visitor Center on May 15, 2025. AP What To Know The U.S. Food and Drug Administration (FDA) gave the green light for mNEXSPIKE (mRNA-1283), Moderna's new lower-dose COVID-19 vaccine, on May 31. Greene, the U.S. representative for Georgia's 14th congressional district, shared Moderna's post about the recent approval with the caption: "Not MAHA at all!!! Unreal." Not MAHA at all!!! Unreal. — Rep. Marjorie Taylor Greene🇺🇸 (@RepMTG) June 1, 2025 She was referring to Kennedy Jr.'s movement Make America Healthy Again, whose mission is to "aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases." Newsweek has contacted the United States Department of Health and Human Services outside of office hours, via email, for comment. The new vaccine is set to be used for adults 65 or older or people between the ages of 12 and 64 with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). Approval for the jab is "based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial which enrolled approximately 11,400 participants aged 12 years and older," Moderna says. It comes after Kennedy Jr. announced that the CDC is no longer encouraging COVID-19 vaccines for pregnant women and healthy children, marking a shift in federal public health guidance. What People Are Saying Chief Executive Officer of Moderna Stéphane Bancel said in a statement: "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." Kennedy Jr. said about the new CDC guidance: "I couldn't be more pleased to announce that as of today the COVID vaccine for healthy children and healthy pregnant women has been removed from the CDC recommended immunization schedule." What Happens Next The new vaccine is expected to be ready for those eligible to take it in time for the 2025-2026 respiratory virus season. You should not get mNEXSPIKE if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (an mRNA vaccine for preventing COVID-19) or any Moderna COVID-19 vaccine or to any ingredient in these vaccines, the company warns.
Yahoo
41 minutes ago
- Yahoo
Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving with innovations like phage display and AI-driven design. The market is booming across North America, Europe, and Asia-Pacific, driven by personalized medicine and rapid advancements in antibody discovery technologies. Antibody Discovery Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Antibody Discovery - Global Strategic Business Report" has been added to global market for Antibody Discovery was valued at US$1.9 Billion in 2024 and is projected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antibody Discovery market. Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase - encompassing target identification, antibody generation, screening, and lead optimization - is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques - ranging from chimerization to full deimmunization - are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific - especially China, South Korea, and Japan - is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases - including rheumatoid arthritis, psoriasis, and Crohn's disease - also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer's, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across Is Fueling the Growth of the Global Antibody Discovery Market?The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market - such as trastuzumab, adalimumab, and pembrolizumab - which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges - can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?Report ScopeThe report analyzes the Antibody Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Antibody Type (Monoclonal, Polyclonal, Other Antibody Types) Service (Phage Display, Hybridoma, Other Services) End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses) Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibody segment, which is expected to reach US$2 Billion by 2030 with a CAGR of a 9.3%. The Polyclonal Antibody segment is also set to grow at 10.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $500.0 Million in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $530.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam, AbCellera Biologics, Ablexis, Adimab, Akeso Biopharma and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities. Key Attributes: Report Attribute Details No. of Pages 224 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $3.3 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines Transgenic Animal Models Expand the Scope of Novel Antibody Generation Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery Data Integration Across Platforms Enhances Efficiency in Antibody Optimization Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery FOCUS ON SELECT PLAYERSSome of the 41 companies featured in this Antibody Discovery market report include: Abcam AbCellera Biologics Inc. Ablexis Adimab Akeso Biopharma Biocytogen Pharmaceuticals Co., Ltd. Bruker Corporation Charles River Laboratories ChemPartner Creative Biolabs Danaher Corporation Eurofins Scientific Evotec SE FairJourney Biologics Genmab GenScript Biotech Corporation Harbour BioMed Icosagen AS ImmunoPrecise Antibodies Ltd. Isogenica Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Discovery Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ScotRail news, interviews and updates on the railway operator
Scotrail is a publicly owned, nationalised rail service operated on by The Scottish Government and overseen by Scottish Rail Holdings Limited. The train service was returned to public ownership in April 2022 after The Scottish Government ended its ten-year contract with Abellio three years early. The Dutch state-owned railway company had been awarded the franchise in 2015 to run until 2025, but the deal was cut short following criticism over cancellations and performance. The contract was worth more than £7 billion, according to the BBC. Read on for all the latest ScotRail news, interviews and updates. As reported by The Herald, here is a selection of the latest ScotRail news stories. Scot Gov declines to reveal cost of Intercity bids process ScotRail warning ahead of Far North Line improvement works ScotRail: Glasgow Central trains face disruption amid issue On-peak travel is generally between 06:00 and 09:15, and 16:30-18:00. Always check with ScotRail before you travel to ensure you have the correct ticket. John Swinney announced the peak train fares in Scotland will be scrapped permanently from from September 1 2025. The First Minister confirmed the policy at Holyrood, following a pilot scheme that removed peak-time ScotRail fares but ended in September last year following 'limited success'. Transport Scotland said the scheme - which was subsidised by the Scottish Government and standardised tickets across the day - 'did not achieve its aims' of persuading more people to car journeys for rail travel. ScotRail's off-peak tickets can be used after 9.15am on weekdays, and at any time on the weekend and on Scottish bank holidays. Some evening travel restrictions apply to off-peak tickets depending on the station or route. Always check with ScotRail before you travel to ensure you have the correct ticket (Image: Archive) The ban on drinking alcohol on ScotRail services is set to come to an end. First Minister John Swinney made the announcement when he made his Programme for Government statement to Holyrood. The document said the ban is 'counter-productive and ineffective'. A press release from the Scottish Government, which also announced the ending of peak train fares, said: "ScotRail peak rail fares abolished and the general alcohol ban on ScotRail trains removed and replaced with time and location restrictions." A blanket ban on drinking alcohol on ScotRail trains was introduced during Covid-19 in November 2020 and was extended 'for the foreseeable future' in 2022. The 24/7 ban prohibited drinking alcohol at any Scottish station or on any ScotRail service. Transport union RMT said ScotRail's ban cannot be 'adequately enforced', and has called on the train operator to tackle anti-social behaviour. The alcohol ban on ScotRail services has been around since November 2020 (Image: Newsquest) Gordon Martin, organiser at RMT Scotland, told The Herald: "It is not the job of rail workers to police the anti-social behaviour of passengers, and it is clear the rules around alcohol consumption cannot be adequately enforced. "What we need is for ScotRail to take real responsibility for dealing with anti-social and violent conduct, and to ensure every assault on staff is treated seriously and prosecuted to the full extent of the law." Domestic pets, such as dogs, cats, or tortoises, are allowed on ScotRail train services. According to the operator's website, up to two pets are allowed, but they must be on a lead or in a travel cage. ScotRail has options for frequent travellers to save money. Train season tickets offer a 40 per cent saving for those commuting five days a week. There are weekly, monthly, or annual options for the Season Tickets. With the removal of peak fares, season tickets were discounted by 20 per cent for a year and that will continue as planned until September. ScotRail say Flexipass provides a 30 per cent discount, allowing 12 single or six return journeys on the same route within 60 days. More information on ScotRail's railcards and tickets is available on its website. ScotRail passengers experiencing delays of 30 minutes or more could be entitled to compensation. This also applies to missed connections caused by ScotRail train delays. Claims must be made within 28 days of the delay.